Form 4: Inmune Bio CFO Granted 300,000 Stock Options

Inmune Bio's CFO, Cory Randall Ellspermann, was granted 300,000 stock options with an exercise price of $1.48, vesting over four years.

Summary

• Cory Randall Ellspermann, Chief Financial Officer (CFO) of Inmune Bio, Inc. (INMB), was granted 300,000 stock options.
• The transaction date for this grant was December 1, 2025.
• Each option has an exercise price of $1.48.
• The options were granted pursuant to the Issuer's Second Amended and Restated 2021 Stock Incentive Plan.
• The vesting schedule dictates that one-fourth (1/4) of the option will vest 12 months from the grant date.
• Thereafter, the remaining unvested options will vest pro rata on a monthly basis over three (3) years (1/36 per month).
• The options will be 100% vested on the four-year anniversary of the grant date.
• The expiration date for these options is November 23, 2035.
• Following this transaction, the CFO beneficially owns 300,000 derivative securities (options).

Sentiment

Score: 7

Explanation: The grant of stock options to the CFO is a positive development as it aligns management's interests with shareholder value creation, providing a long-term incentive for the executive to contribute to the company's success. This is a routine compensation event and not a direct indicator of operational performance.

Positives

• The grant of stock options to the CFO aligns management's long-term interests with those of shareholders, incentivizing value creation.
• The options were granted under an existing, approved equity incentive plan, indicating structured compensation practices.

Future Outlook

The grant of long-term equity incentives to the CFO suggests a strategic focus on retaining key management and aligning their performance with the company's long-term growth objectives.

Industry Context

The grant of stock options is a common practice in the biotechnology and pharmaceutical industries to attract, retain, and motivate executive talent, linking their compensation to the company's stock performance and long-term success.

Comparison to Industry Standards

• Equity compensation, particularly through stock options with multi-year vesting schedules, is a standard component of executive compensation packages across the biotech sector, comparable to practices at companies like Biogen Inc. or Amgen Inc. for aligning executive incentives with shareholder value.
• The vesting schedule, with an initial cliff and subsequent monthly pro-rata vesting over several years, is typical for ensuring long-term commitment and performance from key executives.

Corporate Governance

Stakeholder Impact

• Shareholders: The grant of options to the CFO is intended to align executive interests with shareholder value creation, potentially leading to improved long-term performance.
• Employees: This transaction specifically impacts the CFO's compensation structure, serving as an example of executive incentives within the company.

Next Steps

• The options will begin vesting 12 months from the grant date, with full vesting occurring on the four-year anniversary of the grant date.

Key Dates

Keywords

Inmune Bio, INMB, stock options, CFO, equity compensation, insider transaction, Form 4